VIP (Vasoactive Intestinal Peptide) from Super Human Peptides UK is a highly conserved, 28-amino acid synthetic neuropeptide. Originally isolated from the intestinal tract, it is now known to be widely distributed throughout the central and peripheral nervous systems. In laboratory research, VIP is heavily studied as a profound systemic vasodilator and a master immunomodulator.
Researchers utilize this peptide to investigate its binding to VPAC1 and VPAC2 receptors, which triggers the rapid relaxation of smooth muscle (particularly in the respiratory, cardiovascular, and gastrointestinal tracts). Furthermore, VIP is utilized to study the suppression of pro-inflammatory cytokines (such as TNF-alpha, IL-6, and IL-12) by shifting the immune response from a destructive Th1 state to a protective Th2 state. Produced under GMP-compliant conditions and verified for 99% purity or higher, VIP is an essential model for advanced research into inflammatory bowel disease (IBD), pulmonary hypertension, severe asthma, and autoimmune modulation.
- —Systemic Vasodilator: Potently relaxes smooth muscle in the gastrointestinal, respiratory, and cardiovascular systems.
- —Master Immunomodulator: Shifts the immune system from a pro-inflammatory state to an anti-inflammatory, tissue-protective state.
- —VPAC Receptor Agonist: Binds with high affinity to VPAC1 and VPAC2 receptors across multiple tissue types.
- —Neuroprotective: Studied for its ability to shield neurons from oxidative stress and excitotoxicity.
- —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
- —Quality Standard: GMP / ISO certified manufacturing.
- —Pulmonary Function: Studying the peptide's ability to induce profound bronchodilation and reduce airway inflammation in models of asthma and COPD.
- —Immunomodulation: Investigating the down-regulation of TNF-alpha and nitric oxide production in activated macrophages and T-cells.
- —Gastrointestinal Healing: Preclinical models exploring the restoration of the intestinal epithelial barrier and reduction of mucosal inflammation in IBD (Crohn's and colitis) models.
- —Autoimmune Pathology: Researching the peptide's ability to restore immune tolerance in models of rheumatoid arthritis and multiple sclerosis.
- —Circadian Rhythms: Evaluating VIP's role within the suprachiasmatic nucleus (SCN) of the brain to regulate sleep-wake cycles and systemic neuroendocrine synchronization.
VIP was discovered in 1970 by researchers Dr. Sami Said and Dr. Viktor Mutt, who initially isolated it from porcine intestines and noted its profound blood pressure-lowering effects.
Subsequent laboratory studies revealed that VIP is far more than a gut hormone; it is a critical neurotransmitter and immune-regulating peptide found throughout the entire body. Laboratory and preclinical models demonstrate that VIP administration exerts massive anti-inflammatory and tissue-healing effects. By binding to VPAC receptors on immune cells, it halts the production of tissue-destroying inflammatory cytokines.
In animal models of severe acute respiratory distress, pulmonary hypertension, and induced colitis, VIP has consistently been shown to reverse tissue damage, open restricted airways, and rapidly restore mucosal blood flow. Because it effectively bridges the nervous and immune systems, it remains a primary focus in advanced neuroimmunology and critical care research.
- 1.Said, S.I., & Mutt, V., "Polypeptide with broad biological activity: isolation from small intestine," Science, 1970.
- 2.Delgado, M. et al., "Vasoactive intestinal peptide: neuromodulator and immune effector," Nature Reviews Immunology, 2004.
- 3.Ganea, D. et al., "Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: a biphasic control of the immune response," Trends in Molecular Medicine, 2015.
- 4.Said, S.I., "Vasoactive intestinal peptide (VIP) in asthma and pulmonary hypertension," Annals of the New York Academy of Sciences, 1998.
